Sara Michell Tolaney MD

Oncology•Boston, MA

Breast Cancer, Hematologic Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

Join to View Full Profile

55 Fruit Street Yaw 7604Massachusetts General HospitalBoston, MA 02114
Phone+1 617-726-2782
Fax+1 617-394-3012

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
University of California San Francisco School of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2005 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bicalutamide in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Mar 23
Completed
Phase 2
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 1
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer Start of enrollment: 2011 Oct 01
Active, not recruiting
Phase 2
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer Start of enrollment: 2012 Mar 01
Completed
Phase 2
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
Completed
Phase 1
Cabozantinib for Metastatic Triple Negative BrCa Start of enrollment: 2013 Feb 01
Completed
Phase 2
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
ACTIVE_NOT_RECRUITING
PHASE2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
COMPLETED
PHASE3
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Start of enrollment: 2014 May 19
Completed
Phase 1
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
ACTIVE_NOT_RECRUITING
PHASE3
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Start of enrollment: 2014 Nov 01
Completed
Phase 2
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Start of enrollment: 2016 Mar 09
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Start of enrollment: 2016 Nov 14
ACTIVE_NOT_RECRUITING
PHASE1
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
ACTIVE_NOT_RECRUITING
PHASE1
Ribociclib (LEE011) Rollover Study for Continued Access Start of enrollment: 2016 Dec 15
Recruiting
Phase 2
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Start of enrollment: 2017 Feb 23
ACTIVE_NOT_RECRUITING
PHASE1
CISPLATIN + AZD-1775 In Breast Cancer Start of enrollment: 2017 Jan 18
Completed
Phase 2
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Start of enrollment: 2017 Feb 17
COMPLETED
PHASE1
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2017 Mar 22
Completed
Phase 2
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Start of enrollment: 2017 May 22
Terminated
Phase 2
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Start of enrollment: 2017 Nov 30
Completed
Phase 2
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Start of enrollment: 2018 Jan 30
ACTIVE_NOT_RECRUITING
PHASE2
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer Start of enrollment: 2018 Oct 01
ACTIVE_NOT_RECRUITING
PHASE1
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Start of enrollment: 2019 Mar 08
ACTIVE_NOT_RECRUITING
PHASE2
Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23
ACTIVE_NOT_RECRUITING
PHASE2
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Start of enrollment: 2020 Jul 20
RECRUITING
PHASE2
ATEMPT 2.0: Adjuvant T-DM1 Vs TH Start of enrollment: 2021 Jun 16
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study.
José Pablo Leone, Julieta Leone, Michael J Hassett, Rachel A Freedman, Jorge Avila
Breast Cancer Research and Treatment. 2025-04-01
Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer.
Stephanie L Graff, Sara M Tolaney, Lowell L Hart, Pedram Razavi, Wolfgang Janni
Cancer. 2025-04-01
Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients.
Sarah L Sammons, Thibaut Sanglier, Jose Pablo Leone, Timothy K Erick, Peter Lambert
Journal of the National Cancer Institute. 2025-03-31

Journal Articles

Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology

Lectures

Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
2019 ASCO Annual Meeting - 6/1/2019
New Frontiers in HER2-Positive Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Trial Data Helped Guide Treatment of Stage II-III Triple-Negative Breast CancerDecember 11th, 2024
When or Whether to Give Immunotherapy in Early Breast CancerNovember 19th, 2024
INAVO120 Trial Tests Inavolisib in HR+, HER2-, PIK3C-Alpha-Mutated DiseaseOctober 30th, 2024
Join now to see all